Skip to main content

Journal of Cancer Research and Clinical Oncology

Ausgabe 9/2021

Inhalt (29 Artikel)

Review – Cancer Research

Targeting tumor vascularization: promising strategies for vascular normalization

Ruiqi Zheng, Feifan Li, Fengcen Li, Aihua Gong

Open Access Review – Cancer Research

Cannabinoids in the landscape of cancer

Nagina Mangal, Simon Erridge, Nagy Habib, Anguraj Sadanandam, Vikash Reebye, Mikael Hans Sodergren

Open Access Original Article – Cancer Research

Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer

Wanting Shao, Christina Kuhn, Doris Mayr, Nina Ditsch, Magdalena Kailuwait, Verena Wolf, Nadia Harbeck, Sven Mahner, Udo Jeschke, Vincent Cavaillès, Sophie Sixou

Correction

Correction to: Cytoplasmic LXR expression is an independent marker of poor prognosis for patients with early stage primary breast cancer

Wanting Shao, Christina Kuhn, Doris Mayr, Nina Ditsch, Magdalena Kailuwait, Verena Wolf, Nadia Harbeck, Sven Mahner, Udo Jeschke, Vincent Cavaillès, Sophie Sixou

Open Access Original Article – Cancer Research

Why so few Nobel Prizes for cancer researchers? An analysis of Nobel Prize nominations for German physicians with a focus on Ernst von Leyden and Karl Heinrich Bauer

Nils Hansson, Giacomo Padrini, Friedrich H. Moll, Thorsten Halling, Carsten Timmermann

Open Access Original Article – Cancer Research

Expression of estrogen-related receptors in ovarian cancer and impact on survival

Susanne Schüler-Toprak, Florian Weber, Maciej Skrzypczak, Olaf Ortmann, Oliver Treeck

Original Article – Cancer Research

The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma

Morgan Guénolé, Paolo Bénigni, Vincent Bourbonne, François Lucia, Delphine Legoupil, Olivier Pradier, Laurent Misery, Arnaud Uguen, Ulrike Schick

Open Access Original Article – Cancer Research

PARP inhibition in UV-associated angiosarcoma preclinical models

Marije E. Weidema, Ingrid M. E. Desar, Melissa H. S. Hillebrandt-Roeffen, Anke E. M. van Erp, Mikio Masuzawa, J. W. R. Meyer, M. C. H. Hogenes, Uta E. Flucke, Winette T. A. van der Graaf, Yvonne M. H. Versleijen-Jonkers

Open Access Original Article – Cancer Research

A metal-free salalen ligand with anti-tumor and synergistic activity in resistant leukemia and solid tumor cells via mitochondrial pathway

Sina M. Hopff, Qifang Wang, Corazon Frias, Marie Ahrweiler, Nicola Wilke, Nathalie Wilke, Albrecht Berkessel, Aram Prokop

Original Article – Cancer Research

Lipopolysaccharides increase the risk of colorectal cancer recurrence and metastasis due to the induction of neutrophil extracellular traps after curative resection

Wei-wei Wang, Lipei Wu, Wenying Lu, Wei Chen, Wenhui Yan, Chunrun Qi, Shihai Xuan, Anquan Shang

Zur Zeit gratis COVID-19 Review – Clinical Oncology

Effectiveness of low-dose radiation therapy to improve mortality of COVID-19

Hamid Ghaznavi

Open Access Original Article – Clinical Oncology

Systemic therapy for recurrent and/or metastatic head and neck cancer: a population-based healthcare research study in Thuringia, Germany

Lisa Morkramer, Maren Geitner, Daniel Boeger, Jens Buentzel, Holger Kaftan, Andreas H. Mueller, Thomas Ernst, Orlando Guntinas-Lichius

Original Article – Clinical Oncology

The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement

Burak Bilgin, Mehmet Ali Nahit Şendur, Şebnem Yücel, Mutlu Hizal, Gürkan Güner, Nalan Akyürek, Cihan Erol, Muhammed Bülent Akıncı, Didem Şener Dede, Bülent Yalçın, Sadettin Kılıçkap

Open Access Original Article – Clinical Oncology

Colonoscopy and polypectomy: beside age, size of polyps main factor for long-term risk of colorectal cancer in a screening population

Kathrin Halfter, Lea Bauerfeind, Anne Schlesinger-Raab, Michael Schmidt, Gabriele Schubert-Fritschle, Dieter Hölzel, Jutta Engel

Original Article – Clinical Oncology

Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation

Hong Wang, Xue-Qian Li, Tian-Tian Chu, Shi-Yu Han, Jia-Qian Qi, Ya-Qiong Tang, Hui-Ying Qiu, Cheng-Cheng Fu, Xiao-Wen Tang, Chang-Geng Ruan, De-Pei Wu, Yue Han

Open Access Original Article – Clinical Oncology

Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data

Josias Bastian Grogg, Jordi Nicola Fronzaroli, Pedro Oliveira, Peter-Karl Bode, Anja Lorch, Allaudin Issa, Joerg Beyer, Daniel Eberli, Vijay Sangar, Thomas Hermanns, Noel William Clarke, Christian Daniel Fankhauser

Original Article – Clinical Oncology

Do proton pump inhibitors prevent Barrett’s esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis

Yue Chen, Chenyu Sun, Yile Wu, Xin Chen, Sujatha Kailas, Zeid Karadsheh, Guangyuan Li, Zhichun Guo, Hongru Yang, Lei Hu, Qin Zhou

Original Article – Clinical Oncology

Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma

Tae Hyung Kim, Sangjoon Park, Chai Hong Rim, Chiwhan Choi, Jinsil Seong

Original Article – Clinical Oncology

Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China

Yu Sun, Yuzhu Zheng, Xiaoyun Yang, Ke Xie, Chi Du, Lang He, Yan Gui, Jiangping Fu, Changlin Li, Huiling Zhang, Li Zhu, Jun Bie, Yi Sun, Yu Fu, Yangang Zhou, Feng Shou, Yan Wang, Jiang Zhu

Original Article – Clinical Oncology

One-stitch method vs. traditional method of protective loop ileostomy for rectal cancer: the impact of BMI obesity

Wenting Pei, Huaiping Cui, Zhenjun Liu, Feng Zhao, Xuezhang Zhu, Leping Li, Changqing Jing, Tao Xu, Lipan Peng, Hongqing Zhuo, Yuezhi Chen, Jizhun Zhang

Original Article – Clinical Oncology

Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China

Yang Wang, Bin Lian, Lu Si, ZhiHong Chi, XiNan Sheng, Xuan Wang, LiLi Mao, BiXia Tang, SiMing Li, XieQiao Yan, Xue Bai, Li Zhou, ChuanLiang Cui, Jun Guo

Original Article – Clinical Oncology

Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients

Sun Min Lim, Min Hee Hong, Sang-Jun Ha, Daehee Hwang, Sehyun Chae, Yoon Woo Koh, Eun Chang Choi, Se-Heon Kim, Da-Hee Kim, Sun Och Yoon, Hye Ryun Kim

Open Access Original Article – Clinical Oncology

Multivariate analysis of prognostic factors in patients with nodular melanoma

L. Susok, M. Stücker, F. G. Bechara, E. Stockfleth, T. Gambichler

Open Access Original Article – Clinical Oncology

Cyberknife® hypofractionated stereotactic radiosurgery (CK-hSRS) as salvage treatment for brain metastases

Sergej Telentschak, Daniel Ruess, Stefan Grau, Roland Goldbrunner, Niklas von Spreckelsen, Karolina Jablonska, Harald Treuer, Martin Kocher, Maximilian Ruge

Original Article – Clinical Oncology

Early T-cell precursor acute lymphoblastic leukemia and other subtypes: a retrospective case report from a single pediatric center in China

Xiaoming Liu, Yao Zou, Li Zhang, Xiaojuan Chen, Wenyu Yang, Ye Guo, Yumei Chen, Yingchi Zhang, Xiaofan Zhu

Original Article – Clinical Oncology

Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience

Vineel Bhatlapenumarthi, Anannya Patwari, Antoine J. Harb

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.